

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## BrainAurora Medical Technology Limited

### 脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

## CHANGE OF NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES

### Change of Non-Executive Directors

The board (the “**Board**”) of directors (the “**Directors**”) of BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that:

- (1) Ms. Li Mingqiu has tendered her resignation, with effect from April 15, 2026, from her office as a non-executive Director due to her other work commitments and personal time arrangements; and
- (2) Mr. Li Sirui has tendered his resignation, with effect from April 15, 2026, from his office as a non-executive Director due to his other work commitments and personal time arrangements.

Each of Ms. Li Mingqiu and Mr. Li Sirui has confirmed that there is no disagreement with the Board and there is no matter in respect of her/his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board is pleased to announce that:

- (1) Mr. Yang Fan (楊帆) (“**Mr. Yang**”) has been appointed as a non-executive Director, with effect from April 15, 2026; and
- (2) Ms. Wang Jingbo (王晶菠) (“**Ms. Wang**”) has been appointed as a non-executive Director, with effect from April 15, 2026.

Biographical details of Mr. Yang and Ms. Wang are set out as follows:

**Mr. Yang Fan (楊帆)**, aged 45, graduated from Carleton University with a bachelor's degree in economic in 2004 and obtained a master's degree in business administration from Cheung Kong Graduate School of Business in 2012. He further obtained an executive master's degree of business administration from Guanghua School of Management of Peking University in 2020. Mr. Yang has over 20 years of experience in corporate finance. Since March 2023, he has served as a non-executive director of Immunotech Biopharm Ltd (stock code: 06978.hk), a company listed on the Main Board of the Stock Exchange. Since 2016, he has held a number of senior management position in Tasly Financial Leasing Co., Ltd\* (天士力融資租賃有限公司) and currently serves as its director and president. From 2014 to 2016, he served as the executive director of the aviation investment division of China Minsheng Investment Co., Ltd.\* (中國民生投資股份有限公司) and the director of CM Luxembourg Investment S.A. Prior to that, Mr. Yang has held various senior and managerial positions in a number of financial leasing corporation and financial institutions.

**Ms. Wang Jingbo (王晶菠)**, aged 42, has over 20 years of extensive experience in the field of sales management, with a long-term focus on pharmaceutical marketing and team management. She obtained a master's degree in applied psychology and management from the Brest Business School in 2021. Ms. Wang joined Xi'an Xingye Pharmaceutical Co., Ltd (西安興業醫藥有限公司) in 2006, and has successively served as a sales representative, sales manager, and sales director of the northern China region. Since 2020, she has been the deputy general manager of sales of Xi'an Xingye Pharmaceutical Co., Ltd (西安興業醫藥有限公司).

Each of Mr. Yang and Ms. Wang has signed a letter of appointment with the Company, pursuant to which he/she will hold office until the first annual general meeting of the Company after his/her appointment and shall then be eligible for re-election at such meeting, and thereafter will be subject to retirement by rotation and re-election at the Company's annual general meeting in accordance with the articles of association of the Company. Upon re-election, his/her term of office will be for a period of three years from the date of such annual general meeting. Under the letter of appointment, each of Mr. Yang and Ms. Wang as a non-executive Director may be terminated by three (3) months' notice in writing served by either him/her and the Company. Mr. Yang and Ms. Wang are not entitled to any director's fee under their letters of appointment.

Save as disclosed above, as at the date of this announcement, each of Mr. Yang and Ms. Wang has confirmed that he/she (i) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) does not hold any other position in the Group; (iii) does not have any other major appointments and professional qualifications; (iv) did not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years immediately prior to the date of this announcement; and (v) does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). There is no other information in relation to his/her appointment that needs to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules or any other matter in relation to his/her appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warmest welcome to Mr. Yang and Ms. Wang in joining the Board.

## **Change in Composition of Board Committees**

The Board further announces that the following changes in composition of the Board committees, have taken effect on April 15, 2026:

1. Ms. Li Mingqiu ceased to be a member of the nomination committee of the Board (the “**Nomination Committee**”); and
2. Ms. Wang has been appointed as a member of the Nomination Committee.

Following the above changes, the Nomination Committee comprises Mr. Tan Zheng (譚錚) (chairman), Mr. Tu Lei (涂雷), Dr. Duan Tao (段濤), Mr. Lam Yiu Por (林曉波) and Ms. Wang Jingbo (王晶菠).

By order of the Board  
**BrainAurora Medical Technology Limited**  
**Tan Zheng**  
*Chairman and Executive Director*

Hong Kong, April 15, 2026

*As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive Director; (ii) Mr. Deng Feng, Mr. Yang Fan and Ms. Wang Jingbo as non-executive Directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive Directors.*